Czechia· CZ-0290032
KISUNLA
A donanemab product containing donanemab, registered in Czechia by Eli Lilly Nederland B.V., Utrecht. The same ATC class is registered in 11 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Donanemab is registered in 11 of 19 countries.
Countries holding a registration under ATC N06DX05 (donanemab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Donanemab · ATC N06DX05
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- DONANEMAB
- Manufacturer
- Eli Lilly Nederland B.V., Utrecht
- Country
- Czechia (CZ)
- ATC code
- N06DX05
- ATC class
- Donanemab
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Donanemab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKisunla 350 mgEli Lilly Nederland
- SwitzerlandKisunla 350 mg, Konzentrat zur Herstellung einer InfusionslösungEli Lilly (Suisse) SA
- FinlandKisunlaEli Lilly Nederland B.V.
- IrelandKisunla 350 mg concentrate for solution for infusionEli Lilly Nederland B.V.
- IcelandKisunlaEli Lilly Nederland B.V.*
- PolandKisunla 350 mgEli Lilly Nederland B.V.
- SwedenKisunla 350 mg Koncentrat till infusionsvätska, lösningEli Lilly Nederland B.V.
- United KingdomKisunla 350mg/20ml concentrate for solution for infusion vialsEli Lilly and Company Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kisunla
- Liechtenstein · Kisunla
- Norway · Kisunla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b8b66c9a-a96e-45ac-ac88-39268cf0bd81 GET /v1/drugs/b8b66c9a-a96e-45ac-ac88-39268cf0bd81?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF CNC SOL",
"source": "sukl",
"strength": "350MG",
"pack_size": "2(2X1)X20ML",
"substance": "DONANEMAB",
"cz_kod_sukl": "0290032",
"product_type": "BT",
"substance_codes": "22108",
"registration_state": "R",
"registration_number": "EU/1/25/1926/002"
}See everything about donanemab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.